Syros Pharmaceuticals
Financials
Estimates*
| USD | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Revenues | 15.1m | 23.5m | 14.9m | 9.9m | 2.8m | - | 151m |
| % growth | 662 % | 56 % | (37 %) | (33 %) | (72 %) | - | - |
| EBITDA | (78.8m) | (96.3m) | (131m) | (117m) | - | - | - |
| % EBITDA margin | (522 %) | (410 %) | (879 %) | (1182 %) | - | - | - |
| Profit | (84.0m) | (86.6m) | (94.7m) | (165m) | (82.4m) | (120m) | (102m) |
| % profit margin | (557 %) | (369 %) | (636 %) | (1656 %) | (2942 %) | - | (67 %) |
| EV / revenue | 40.3x | 4.8x | 4.9x | 10.3x | 5.9x | - | 0.3x |
| EV / EBITDA | -7.7x | -1.2x | -0.6x | -0.9x | - | - | - |
| R&D budget | 76.1m | 99.9m | 112m | 108m | - | - | - |
| R&D % of revenue | 504 % | 425 % | 752 % | 1088 % | - | - | - |
Source: Dealroom estimates
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | N/A | - | |
$30.0m | Series A | ||
$53.0m | Series B | ||
$40.0m | Series C | ||
| N/A | N/A | IPO | |
| N/A | $35.0m | Post IPO Equity | |
| N/A | $11.4m | Post IPO Equity | |
$60.0m | Debt | ||
$90.5m | Post IPO Equity | ||
* | $130m | Private Placement VC | |
* | $45.0m | Post IPO Equity | |
| Total Funding | $253m | ||
Related Content
Recent News about Syros Pharmaceuticals
EditSyros Pharmaceuticals is a biopharmaceutical company focused on developing innovative gene control medicines to treat cancer and genetic diseases. The company operates in the healthcare and biotechnology market, primarily serving patients with acute myeloid leukemia and select solid tumors. Syros' business model revolves around the research, development, and commercialization of small molecule therapies that precisely control gene expression. The company generates revenue through partnerships, licensing agreements, and potential future sales of its proprietary medicines. Syros is advancing a pipeline that includes two investigational medicines in clinical trials and multiple programs in preclinical development. The company's approach leverages its expertise in gene control to create targeted therapies that aim to transform patient outcomes.
Keywords: gene control, small molecules, cancer therapy, genetic diseases, biopharmaceutical, acute myeloid leukemia, solid tumors, clinical trials, biotechnology, innovative medicines.
